Frontiers in Immunology (Sep 2020)
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
- Bárbara Soria-Juan,
- Natalia Escacena,
- Vivian Capilla-González,
- Yolanda Aguilera,
- Lucía Llanos,
- Juan R. Tejedo,
- Juan R. Tejedo,
- Francisco J. Bedoya,
- Francisco J. Bedoya,
- Verónica Juan,
- Antonio De la Cuesta,
- Rafael Ruiz-Salmerón,
- Enrique Andreu,
- Lukas Grochowicz,
- Felipe Prósper,
- Fermín Sánchez-Guijo,
- Francisco S. Lozano,
- Manuel Miralles,
- Lourdes Del Río-Solá,
- Gregorio Castellanos,
- José M. Moraleda,
- Robert Sackstein,
- Mariano García-Arranz,
- Damián García-Olmo,
- Franz Martín,
- Franz Martín,
- Abdelkrim Hmadcha,
- Abdelkrim Hmadcha,
- Bernat Soria,
- Bernat Soria,
- Bernat Soria,
- the Collaborative Working Group “Noma Project Team”
Affiliations
- Bárbara Soria-Juan
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Natalia Escacena
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Vivian Capilla-González
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Yolanda Aguilera
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Lucía Llanos
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Juan R. Tejedo
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Juan R. Tejedo
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Francisco J. Bedoya
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Francisco J. Bedoya
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Verónica Juan
- Andalusian eHealth Library, Sevilla, Spain
- Antonio De la Cuesta
- Unidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, Spain
- Rafael Ruiz-Salmerón
- Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, Spain
- Enrique Andreu
- Clínica Universidad de Navarra, Pamplona, Spain
- Lukas Grochowicz
- Clínica Universidad de Navarra, Pamplona, Spain
- Felipe Prósper
- Clínica Universidad de Navarra, Pamplona, Spain
- Fermín Sánchez-Guijo
- IBSAL-Hospital Universitario Salamanca, Salamanca, Spain
- Francisco S. Lozano
- IBSAL-Hospital Universitario Salamanca, Salamanca, Spain
- Manuel Miralles
- Department of Surgery, University of Valencia, Valencia, Spain
- Lourdes Del Río-Solá
- 0Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain
- Gregorio Castellanos
- 1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- José M. Moraleda
- 1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- Robert Sackstein
- 2Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States
- Mariano García-Arranz
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Damián García-Olmo
- Fundación Jiménez Díaz Health Research Institute, Madrid, Spain
- Franz Martín
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Franz Martín
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Abdelkrim Hmadcha
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Abdelkrim Hmadcha
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Bernat Soria
- Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain
- Bernat Soria
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
- Bernat Soria
- 3ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain
- the Collaborative Working Group “Noma Project Team”
- DOI
- https://doi.org/10.3389/fimmu.2020.02029
- Journal volume & issue
-
Vol. 11
Abstract
No abstracts available.Keywords
- cellular medicaments
- cell-based therapy
- clinical trials
- diabetes
- critical limb ischemia
- cost-effective